|
110 Companies |
|
139 Products |
|
139 Products |
|
95 Mechanisms of Action |
|
2 Trials |
|
919 News |
|
| «12...345678910111213...1819» |
- |||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment open: A Study of Golimumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Oct 4, 2014
P3, N=440, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial initiation date, Trial primary completion date: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (clinicaltrials.gov) - Oct 2, 2014
P1b, N=16, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Not yet recruiting --> Recruiting Initiation date: Jun 2014 --> Sep 2014 | Trial primary completion date: May 2015 --> Oct 2015
- Biomarker, New P1 trial: Evaluate the Effect of Elimune Capsules (clinicaltrials.gov) - Sep 29, 2014
P1, N=20, Recruiting, Sponsor: Elorac, Inc.
- Xeljanz (tofacitinib) / Pfizer, PF-06263276 / Pfizer
Clinical: A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis (clinicaltrials.gov) - Sep 28, 2014
P1, N=20, Recruiting, Sponsor: Pfizer
Initiation date: Jun 2014 --> Sep 2014 | Trial primary completion date: May 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- ||| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim
Enrollment closed: BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab (clinicaltrials.gov) - Sep 22, 2014
P2, N=169, Active, not recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | anti-TNF/IL-17A FynomAb (COVA322) / J&J
New P1/2 trial: Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - Sep 19, 2014
P1/2, N=39, Recruiting, Sponsor: Covagen
- |||||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Enrollment open: NAVIGATE: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (clinicaltrials.gov) - Sep 19, 2014
P3, N=800, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| namilumab (IZN-101) / Amgen, Izana Biosci
Clinical: Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis (clinicaltrials.gov) - Sep 15, 2014
P2, N=100, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Clinical: Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis (clinicaltrials.gov) - Sep 15, 2014
P=N/A, N=1100, Recruiting, Sponsor: Amgen
- ||||| Cosentyx (secukinumab) / Novartis
Enrollment closed: Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab (clinicaltrials.gov) - Sep 15, 2014
P3, N=1152, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Enbrel (etanercept) / Pfizer, Amgen
Phase classification: Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=128, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Phase classification: P4 --> P=N/A
- | tazarotene topical / Generic mfg.
New P2 trial: Efficacy and Safety of Tazarotene Gel in Nail Psoriasis (clinicaltrials.gov) - Sep 10, 2014
P2, N=60, Recruiting, Sponsor: Almirall, S.A.
- sonelokimab (M1095) / Avillion, MoonLake Immunotherap
Enrollment open: Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects (clinicaltrials.gov) - Sep 9, 2014
P1, N=40, Recruiting, Sponsor: Merck KGaA
Phase classification: P4 --> P=N/A Not yet recruiting --> Recruiting
- Clinical: Vascular Effects of Achieving Minimal Disease Activity in Psoriatic Arthritis - a 2 Year Prospective Cohort Study (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=100, Recruiting, Sponsor: Chinese University of Hong Kong
- ||||| pefcalcitol (M 518101) / Maruho
Enrollment closed, Trial primary completion date: Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients (clinicaltrials.gov) - Sep 4, 2014
P3, N=725, Active, not recruiting, Sponsor: Maruho Europe Limited
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014
- Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Enrollment change: RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization (clinicaltrials.gov) - Aug 29, 2014
P4, N=294, Terminated, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014 N=900 --> 294
- Trial completion, Enrollment change: Exploratory Study of Natural Killer Cells in Human Skin (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=28, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
N=900 --> 294 Recruiting --> Completed | N=100 --> 28
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Enrollment change, Trial primary completion date, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Aug 28, 2014
P=N/A, N=140, Recruiting, Sponsor: AbbVie
Recruiting --> Completed | N=100 --> 28 Active, not recruiting --> Recruiting | N=80 --> 140 | Trial primary completion date: Feb 2015 --> Jul 2016
- |||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Trial primary completion date: Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 26, 2014
P3, N=350, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Recruiting | N=80 --> 140 | Trial primary completion date: Feb 2015 --> Jul 2016 Trial primary completion date: Aug 2015 --> Jul 2014
- | neihulizumab (ALTB-168) / AltruBio
New P2 trial: A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Aug 22, 2014
P2, N=48, Recruiting, Sponsor: AbGenomics B.V Taiwan Branch
- || Enrollment closed: Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=90, Active, not recruiting, Sponsor: University of Aarhus
Trial primary completion date: Aug 2015 --> Jul 2014 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Improving Psoriasis Through Health and Well-Being (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=130, Completed, Sponsor: University of Rochester
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=200 --> 130 | Trial primary completion date: Jul 2014 --> Dec 2013
- Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change: A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=29, Completed, Sponsor: Dr. FRANCISCO J. BLANCO-GARCIA
Active, not recruiting --> Completed | N=200 --> 130 | Trial primary completion date: Jul 2014 --> Dec 2013 Active, not recruiting --> Completed | N=168 --> 29
- |||| DLX105 / Novartis, Athenex
Trial completion: Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients (clinicaltrials.gov) - Aug 12, 2014
P2, N=59, Completed, Sponsor: Delenex Therapeutics AG
Active, not recruiting --> Completed | N=168 --> 29 Recruiting --> Completed
- ||||| Cosentyx (secukinumab) / Novartis
Enrollment closed: CLEAR: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis (clinicaltrials.gov) - Aug 12, 2014
P3, N=679, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Active, not recruiting
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial primary completion date: Use of Botulinum Toxin to Treat Psoriasis (clinicaltrials.gov) - Aug 8, 2014
P1, N=10, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Dec 2014
- |||| pefcalcitol (M 518101) / Maruho
Trial primary completion date: Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis (clinicaltrials.gov) - Aug 6, 2014
P3, N=360, Recruiting, Sponsor: Maruho North America Inc.
Trial primary completion date: Jun 2014 --> Dec 2014 Trial primary completion date: Feb 2015 --> Sep 2015
- ||||| New P2 trial, IO biomarker: BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis (clinicaltrials.gov) - Aug 6, 2014
P2, N=182, Completed, Sponsor: Boehringer Ingelheim
- |||| pefcalcitol (M 518101) / Maruho
Trial primary completion date: Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis (clinicaltrials.gov) - Aug 5, 2014
P3, N=522, Recruiting, Sponsor: Maruho North America Inc.
Trial primary completion date: Feb 2015 --> Sep 2015 Trial primary completion date: Mar 2014 --> Dec 2014
- |||| pefcalcitol (M 518101) / Maruho
Trial primary completion date: Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis (clinicaltrials.gov) - Aug 5, 2014
P3, N=522, Recruiting, Sponsor: Maruho North America Inc.
Trial primary completion date: Mar 2014 --> Dec 2014 Trial primary completion date: Mar 2014 --> Dec 2014
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=500, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Mar 2014 --> Dec 2014 Active, not recruiting --> Completed
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Trial primary completion date, HEOR: Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=926, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Dec 2013
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: Tofacitinib Ointment For Chronic Plaque Psoriasis (clinicaltrials.gov) - Aug 1, 2014
P2, N=480, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Dec 2013 Active, not recruiting --> Recruiting
- Enrollment change: Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications (clinicaltrials.gov) - Jul 30, 2014
P2, N=5, Terminated, Sponsor: University of Tennessee
Active, not recruiting --> Recruiting N=40 --> 5
- |||||||||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
New P3 trial: NAVIGATE: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (clinicaltrials.gov) - Jul 30, 2014
P3, N=800, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||||| Cibinqo (abrocitinib) / Pfizer
New P2 trial: Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis (clinicaltrials.gov) - Jul 29, 2014
P2, N=196, Not yet recruiting, Sponsor: Pfizer
- Enrollment closed: IL-17 Role in Variants of Psoriasis (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=90, Active, not recruiting, Sponsor: Innovaderm Research Inc.
N=40 --> 5 Recruiting --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis (clinicaltrials.gov) - Jul 24, 2014
P4, N=106, Active, not recruiting, Sponsor: Innovaderm Research Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Trial completion, Trial primary completion date, HEOR: Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=105, Completed, Sponsor: Innovaderm Research Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014
- |||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Enrollment change, Trial primary completion date: Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments (clinicaltrials.gov) - Jul 24, 2014
P4, N=89, Completed, Sponsor: Innovaderm Research Inc.
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014 Active, not recruiting --> Completed | N=150 --> 89 | Trial primary completion date: Dec 2013 --> Jul 2014
- |||| calcipotriol/betamethasone dipropionate / Generic mfg.
Enrollment open: An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects (clinicaltrials.gov) - Jul 24, 2014
P2, N=100, Recruiting, Sponsor: LEO Pharma
Active, not recruiting --> Completed | N=150 --> 89 | Trial primary completion date: Dec 2013 --> Jul 2014 Not yet recruiting --> Recruiting
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial, Real-world evidence, Real-world: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (clinicaltrials.gov) - Jul 23, 2014
P3, N=200, Recruiting, Sponsor: AbbVie
- Clinical: A Single-Center, Prospective, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=30, Completed, Sponsor: Bagel, Jerry, M.D.
- ||||| Cosentyx (secukinumab) / Novartis
Trial initiation date: CLEAR: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis (clinicaltrials.gov) - Jul 18, 2014
P3, N=640, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: May 2011 --> Feb 2014
- | Xeljanz (tofacitinib) / Pfizer, PF-06263276 / Pfizer
Clinical: A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis (clinicaltrials.gov) - Jul 18, 2014
P1, N=20, Not yet recruiting, Sponsor: Pfizer
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis (clinicaltrials.gov) - Jul 16, 2014
P4, N=128, Recruiting, Sponsor: Pfizer
- acitretin / Generic mfg.
Clinical: Efficacy and Safety Study of Total Glucosides of Paeony Combined With Acitretin to Treat Psoriasis (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=108, Completed, Sponsor: Xijing Hospital
- calcipotriol/betamethasone dipropionate / Generic mfg.
Clinical: Efficacy and Safety Study of Calcipotriol Betamethasone Plus Calcipotriol in Sequential Therapy to Psoriasis (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=230, Completed, Sponsor: Xijing Hospital
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (clinicaltrials.gov) - Jul 14, 2014
P1b, N=16, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Initiation date: May 2011 --> Feb 2014 Not yet recruiting --> Recruiting
- metformin / Generic mfg.
Clinical: Metformin in Psoriatic Arthritis (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=56, Completed, Sponsor: Faculty of Medicine, University of Alexandria